# Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

> **NCT01787500** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 47 (actual)

## Conditions studied

- BRAF NP_004324.2:p.V600X
- KRAS wt Allele
- Metastatic Malignant Solid Neoplasm
- Stage IV Colorectal Cancer AJCC v7
- Stage IVA Colorectal Cancer AJCC v7
- Stage IVB Colorectal Cancer AJCC v7
- Unresectable Solid Neoplasm

## Interventions

- **BIOLOGICAL:** Cetuximab
- **DRUG:** Irinotecan Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01787500
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-15
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-01-19
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01787500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01787500, "Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01787500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*